Clinical trial
Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia
NCT00202007 · Otsuka Beijing Research Institute, Industry · Completed
Key facts
| NCT number | NCT00202007 |
|---|---|
| Title | Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia |
| Official title | A Multi-Center, Randomized, Double-Blind Study, Comparing With Risperidone, to Evaluate the Efficacy and Safety of Aripiprazole in the Treatment of Patients With Schizophrenia |
| Lead sponsor | Otsuka Beijing Research Institute, Industry |
| Collaborators | Zhejiang Otsuka Pharmaceutical Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Aripiprazole tablet, 5-30mg/day, oral, 6 weeks, Risperidone tablet, 1-6mg/day |
| Enrollment | 240 |
| Start date | Feb 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Sep 20, 2005 |
| Last update posted | Nov 1, 2023 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: